[1]
|
Adam, R., De Gramont, A., Figueras, J., Guthrie, A., Kokudo, N., Kunstlinger, F., et al. (2012) The Oncosurgery Ap-proach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus. Oncologist, 17, 1225-1239. https://doi.org/10.1634/theoncologist.2012-0121
|
[2]
|
Sung, J.J., Lau, J.Y., Goh, K.L., Leung, W.K. and Asia Pacific Working Group on Colorectal Cancer (2005) Increasing Incidence of Colorectal Cancer in Asia: Impli-cations for Screening. The Lancet Oncology, 6, 871-876.
https://doi.org/10.1016/S1470-2045(05)70422-8
|
[3]
|
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J. and Cervantes, A. (2022) Clinical Management of Metastatic Colorectal Cancer in the Era of Precision Medicine. CA: A Cancer Journal for Clinicians, 72, 372-401.
https://doi.org/10.3322/caac.21728
|
[4]
|
Biller, L.H. and Schrag, D. (2021) Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA, 325, 669-685. https://doi.org/10.1001/jama.2021.0106
|
[5]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[6]
|
Gallagher, D.J. and Kemeny, N. (2010) Metastatic Colorectal Cancer: From Improved Survival to Potential Cure. Oncology, 78, 237-248. https://doi.org/10.1159/000315730
|
[7]
|
Riedesser, J.E., Ebert, M.P. and Betge, J. (2022) Precision Medicine for Metastatic Colorectal Cancer in Clinical Practice. Therapeu-tic Advances in Medical Oncology, 14, 1-25. https://doi.org/10.1177/17588359211072703
|
[8]
|
Brodsky, F.M. (1988) Monoclonal Antibodies as Magic Bullets. Pharmaceutical Research, 5, 1-9.
https://doi.org/10.1023/A:1015860525341
|
[9]
|
顾艳宏, 姜争, 李健, 邱萌. 结直肠癌靶向治疗中国专家共识[J]. 中华普通外科学文献(电子版), 2023, 17(1): 1-8.
|
[10]
|
Chen, Y.F., Yu, Z.L., Lv, M.Y., Cai, Z.R., Zou, Y.F., Lan, P., et al. (2021) Cancer-Associated Fibroblasts Impact the Clinical Outcome and Treatment Response in Colorectal Can-cer via Immune System Modulation: A Comprehensive Genome-Wide Analysis. Molecular Medicine, 27, Article No. 139. https://doi.org/10.1186/s10020-021-00402-3
|
[11]
|
Bhat, A.A., Nisar, S., Singh, M., Ashraf, B., Masoodi, T., Prasad, C.P., et al. (2022) Cytokine- and Chemokine-Induced Inflammatory Colorectal Tumor Microenvironment: Emerging Avenue for Targeted Therapy. Cancer Communications, 42, 689-715. https://doi.org/10.1002/cac2.12295
|
[12]
|
Balkwill, F.R., Capasso, M. and Hagemann, T. (2012) The Tumor Micro-environment at a Glance. Journal of Cell Science, 125, 5591-5596. https://doi.org/10.1242/jcs.116392
|
[13]
|
Jin, M.Z. and Jin, W.L. (2020) The Updated Landscape of Tumor Microenvironment and Drug Repurposing. Signal Transduction and Targeted Therapy, 5, Article No.166. https://doi.org/10.1038/s41392-020-00280-x
|
[14]
|
Shi, Y., Gao, W., Lytle, N.K., Huang, P., Yuan, X., Dann, A.M., et al. (2019) Targeting LIF-Mediated Paracrine Interaction for Pancreatic Cancer Therapy and Monitoring. Nature, 569, 131-135.
https://doi.org/10.1038/s41586-019-1130-6
|
[15]
|
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., et al. (2012) Tumour Micro-Environment Elicits Innate Resistance to RAF Inhibitors through HGF Secretion. Na-ture, 487, 500-504.
https://doi.org/10.1038/nature11183
|
[16]
|
Bruzzese, F., Hägglöf, C., Leone, A., Sjöberg, E., Roca, M.S., Kiflema-riam, S., et al. (2014) Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 74, 3408-3417.
https://doi.org/10.1158/0008-5472.CAN-13-2259
|
[17]
|
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D.G., Egeblad, M., Evans, R.M., et al. (2020) A Framework for Advancing Our Understanding of Cancer-Associated Fibro-blasts. Nature Reviews Cancer, 20, 174-186.
https://doi.org/10.1038/s41568-019-0238-1
|
[18]
|
Zhong, B., Cheng, B., Huang, X., Xiao, Q., Niu, Z., Chen, Y.F., et al. (2021) Colorectal Cancer-Associated Fibroblasts Promote Metastasis by Up-Regulating LRG1 through Stromal IL-6/STAT3 Signaling. Cell Death & Disease, 13, Article No. 16. https://doi.org/10.1038/s41419-021-04461-6
|
[19]
|
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., et al. (2021) Crosstalk between Cancer-Associated Fibroblasts and Immune Cells in the Tumor Microenvironment: New Findings and Future Perspectives. Molecular Cancer, 20, Article No. 131. https://doi.org/10.1186/s12943-021-01428-1
|
[20]
|
Cassetta, L. and Pollard, J.W. (2020) Tumor-Associated Macro-phages. Current Biology, 30, R246-R248.
https://doi.org/10.1016/j.cub.2020.01.031
|
[21]
|
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M. and Kzhyshkowska, J.J.O. (2019) Interaction of Tumor-Associated Macrophages and Cancer Chemotherapy. OncoIm-munology, 8, e1596004.
https://doi.org/10.1080/2162402X.2019.1596004
|
[22]
|
Zhu, X., Liang, R., Lan, T., Ding, D., Huang, S., Shao, J., et al. (2022) Tumor-Associated Macrophage-Specific CD155 Contributes to M2-Phenotype Transition, Immunosuppres-sion, and Tumor Progression in Colorectal Cancer. Journal for Immunotherapy of Cancer, 10, e004219. https://doi.org/10.1136/jitc-2021-004219
|
[23]
|
Wang, H., Tian, T. and Zhang, J. (2021) Tumor-Associated Macro-phages (TAMs) in Colorectal Cancer (CRC): From Mechanism to Therapy and Prognosis. International Journal of Mo-lecular Sciences, 22, Article 8470.
https://doi.org/10.3390/ijms22168470
|
[24]
|
Fu, L.Q., Du, W.L., Cai, M.H., Yao, J.Y., Zhao, Y.Y. and Mou, X.Z. (2020) The Roles of Tumor-Associated Macrophages in Tumor Angiogenesis and Metastasis. Cellular Immunology, 353, Article ID: 104119.
https://doi.org/10.1016/j.cellimm.2020.104119
|
[25]
|
Zhao, S., Mi, Y., Guan, B., Zheng, B., Wei, P., Gu, Y., et al. (2020) Tumor-Derived Exosomal miR-934 Induces Macrophage M2 Polarization to Promote Liver Metastasis of Colo-rectal Cancer. Journal of Hematology & Oncology, 13, Article No. 156. https://doi.org/10.1186/s13045-020-00991-2
|
[26]
|
Zhang, N., Ng, A.S., Cai, S., Li, Q., Yang, L. and Kerr, D. (2021) Novel Therapeutic Strategies: Targeting Epithelial-Mesenchymal Transition in Colorectal Cancer. The Lancet On-cology, 22, e358-e368.
https://doi.org/10.1016/S1470-2045(21)00343-0
|
[27]
|
Dongre, A. and Weinberg, R.A. (2019) New Insights into the Mechanisms of Epithelial-Mesenchymal Transition and Implications for Cancer. Nature Reviews Molecular Cell Bi-ology, 20, 69-84.
https://doi.org/10.1038/s41580-018-0080-4
|
[28]
|
Fumagalli, A., Oost, K.C., Kester, L., Morgner, J., Bornes, L., Bruens, L., et al. (2020) Plasticity of Lgr5-Negative Cancer Cells Drives Metastasis in Colorectal Cancer. Cell Stem Cell, 26, 569-578.E7.
https://doi.org/10.1016/j.stem.2020.02.008
|
[29]
|
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., et al. (2021) Circulating Tumor Cells: Biology and Clinical Significance. Signal Transduction and Targeted Therapy, 6, Article No. 404.
https://doi.org/10.1038/s41392-021-00817-8
|
[30]
|
Leblanc, R. and Peyruchaud, O. (2016) Metastasis: New Func-tional Implications of Platelets and Megakaryocytes. Blood, 128, 24-31. https://doi.org/10.1182/blood-2016-01-636399
|
[31]
|
Mizuno, R., Kawada, K., Itatani, Y., Ogawa, R., Kiyasu, Y. and Sakai, Y. (2019) The Role of Tumor-Associated Neutrophils in Colorectal Cancer. International Journal of Molecu-lar Sciences, 20, Article 529.
https://doi.org/10.3390/ijms20030529
|
[32]
|
Gong, L., Cai, Y., Zhou, X. and Yang, H. (2012) Activated Platelets Interact with Lung Cancer Cells through P-Selectin Glycoprotein Ligand-1. Pathology & Oncology Research, 18, 989-996.
https://doi.org/10.1007/s12253-012-9531-y
|
[33]
|
Brodt, P. (2016) Role of the Microenvironment in Liver Metasta-sis: From Pre- to Prometastatic Niches. Clinical Cancer Research, 22, 5971-5982. https://doi.org/10.1158/1078-0432.CCR-16-0460
|
[34]
|
Auguste, P., Fallavollita, L., Wang, N., Burnier, J., Bikfalvi, A. and Brodt, P. (2007) The Host Inflammatory Response Promotes Liver Metastasis by Increasing Tumor Cell Arrest and Extravasation. The American Journal of Pathology, 170, 1781-1792. https://doi.org/10.2353/ajpath.2007.060886
|
[35]
|
Khatib, A.M., Auguste, P., Fallavollita, L., Wang, N., Samani, A., Kontogiannea, M., et al. (2005) Characterization of the Host Proinflammatory Response to Tumor Cells during the Initial Stages of Liver Metastasis. The American Journal of Pathology, 167, 749-759. https://doi.org/10.1016/S0002-9440(10)62048-2
|
[36]
|
Benedicto, A., Herrero, A., Romayor, I., Marquez, J., Smedsrød, B., Olaso, E., et al. (2019) Liver Sinusoidal Endothelial Cell ICAM-1 Mediated Tumor/Endothelial Crosstalk Drives the Development of Liver Metastasis by Initiating Inflammatory and Angiogenic Responses. Scientific Reports, 9, Article No. 13111.
https://doi.org/10.1038/s41598-019-49473-7
|
[37]
|
郭慧娴, 周慧玲, 朱晓蔚, 于鸿. 结直肠癌分子靶向治疗的研究进展[J]. 癌症进展, 2022, 20(19): 1950-1953.
|
[38]
|
Riechelmann, R. and Grothey, A. (2017) Antiangiogenic Therapy for Refractory Colorectal Cancer: Current Options and Future Strategies. Therapeutic Advances in Medical On-cology, 9, 106-126.
https://doi.org/10.1177/1758834016676703
|
[39]
|
Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. https://doi.org/10.1007/s11523-017-0518-1
|
[40]
|
Cunningham, D., Lang, I., Marcuello, E., Lorusso, V., Ocvirk, J., Shin, D.B., et al. (2013) Bevacizumab plus Capecitabine versus Capecitabine Alone in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer (AVEX): An Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 14, 1077-1085.
https://doi.org/10.1016/S1470-2045(13)70154-2
|
[41]
|
Tebbutt, N.C., Wilson, K., Gebski, V.J., Cummins, M.M., Zannino, D., van Hazel, G.A., et al. (2010) Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Meta-static Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 28, 3191-3198.
https://doi.org/10.1200/JCO.2009.27.7723
|
[42]
|
Folprecht, G., Pericay, C., Saunders, M.P., Thomas, A., Lopez Lopez, R., Roh, J.K., et al. (2016) Oxaliplatin and 5-FU/Folinic Acid (Modified FOLFOX6) with or without Aflibercept in First-Line Treatment of Patients with Metastatic Colorectal Cancer: The AFFIRM Study. Annals of Oncology, 27, 1273-1279.
https://doi.org/10.1093/annonc/mdw176
|
[43]
|
Chan, D.L.H., Segelov, E., Wong, R.S., Smith, A., Herbertson, R.A., Li, B.T., et al. (2017) Epidermal Growth Factor Receptor (EGFR) Inhibitors for Metastatic Colorectal Cancer. The Cochrane Database of Systematic Reviews, 6, CD007047. https://doi.org/10.1002/14651858.CD007047.pub2
|
[44]
|
Mendelsohn, J., Prewett, M., Rockwell, P. and Goldstein, N.I. (2015) CCR 20th Anniversary Commentary: A Chimeric Antibody, C225, Inhibits EGFR Activation and Tumor Growth. Clinical Cancer Research, 21, 227-229.
https://doi.org/10.1158/1078-0432.CCR-14-2491
|
[45]
|
Yarom, N. and Jonker, D.J. (2011) The Role of the Epider-mal Growth Factor Receptor in the Mechanism and Treatment of Colorectal Cancer. Discovery Medicine, 11, 95-105.
|
[46]
|
Richman, S.D., Southward, K., Chambers, P., Cross, D., Barrett, J., Hemmings, G., et al. (2016) HER2 Overexpression and Amplification as a Potential Therapeutic Target in Colorectal Cancer: Analysis of 3256 Patients En-rolled in the QUASAR, FOCUS and PICCOLO Colorectal Cancer Trials. The Journal of Pathology, 238, 562-570.
https://doi.org/10.1002/path.4679
|
[47]
|
Nowak, J.A. (2020) HER2 in Colorectal Carcinoma: Are We There Yet? Surgical Pathology Clinics, 13, 485-502.
https://doi.org/10.1016/j.path.2020.05.007
|
[48]
|
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., et al. (2011) Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Anti-body Cetuximab. Science Translational Medicine, 3, 99ra86. https://doi.org/10.1126/scitranslmed.3002442
|
[49]
|
杨国华. 结直肠癌分子靶向治疗研究进展[J]. 中国老年学杂志, 2021, 41(22): 5164-5168.
|
[50]
|
Huang, W., Chen, Y., Chang, W., Ren, L., Tang, W., Zheng, P., et al. (2022) HER2 Positivity as a Biomarker for Poor Prognosis and Unre-sponsiveness to Anti-EGFR Therapy in Colorectal Cancer. Journal of Cancer Research and Clinical Oncology, 148, 993-1002. https://doi.org/10.1007/s00432-021-03655-x
|
[51]
|
Sanz-Garcia, E., Argiles, G., Elez, E. and Tabernero, J. (2017) BRAF Mutant Colorectal Cancer: Prognosis, Treatment, and New Perspectives. Annals of Oncology, 28, 2648-2657. https://doi.org/10.1093/annonc/mdx401
|
[52]
|
Kopetz, S., Desai, J., Chan, E., Hecht, J.R., O’Dwyer, P.J., Maru, D., et al. (20150 Phase II Pilot Study of Vemurafenib in Patients with Metastatic BRAF-Mutated Colorectal Cancer. Journal of Clinical Oncology, 33, 4032-4038.
https://doi.org/10.1200/JCO.2015.63.2497
|
[53]
|
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., et al. (2017) Mechanisms of Resistance to Anti-EGFR Therapy in Colorectal Cancer. Oncotarget, 8, 3980-4000. https://doi.org/10.18632/oncotarget.14012
|
[54]
|
Kopetz, S., Guthrie, K.A., Morris, V.K., Lenz, H.J., Magliocco, A.M., Maru, D., et al. (2021) Randomized Trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). Journal of Clinical Oncology, 39, 285-294. https://doi.org/10.1200/JCO.20.01994
|
[55]
|
O’Brien, P. and O’Connor, B.F. (2008) Seprase: An Overview of an Important Matrix Serine Protease. Biochimica et Biophysica Acta, 1784, 1130-1145. https://doi.org/10.1016/j.bbapap.2008.01.006
|
[56]
|
Wen, Y., Wang, C.T., Ma, T.T., Li, Z.Y., Zhou, L.N., Mu, B., et al. (2010) Immunotherapy Targeting Fibroblast Activation Protein Inhibits Tumor Growth and Increases Survival in a Murine Colon Cancer Model. Cancer Science, 101, 2325-2332. https://doi.org/10.1111/j.1349-7006.2010.01695.x
|
[57]
|
Hofheinz, R.D., Al-Batran, S.E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., et al. (2003) Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer. Onkologie, 26, 44-48. https://doi.org/10.1159/000069863
|